university website

A.C. Ludolph (Albert), J. Kassubek (Jan), B.G. Landwehrmeyer, E. Mandelkow (Eckhard Maria), D.J. Burn (David), D. Caparros-Lefebvre (Dominique), K.A. Frey, J.G. de Yebenes (Justo Garcia), T. Gasser (Thomas), P. Heutink (Peter), et al. G. Hoglinger (Gunter), Z. Jamrozik (Zygmunt), K.A. Jellinger, A. Kazantsev (Alex), H. Kretzschmar (Hans), A.E. Lang, I. Litvan, J.J. Lucas, P.L. McGeer, S. Melquist (Stacey), W. Oertel, M. Otto (Markus), D. Paviour (Dominic), T. Reum (Torsten), A. Saint-Raymond, J.C. Steele, M. Tolnay (Markus), H. Tumani (Hayrettin), J.C. van Swieten (John), M.T. Vanier (Marie Therese), J.P. Vonsattel (Jean Paul), S. Wagner (Stephan) and Z.K. Wszolek (Zbigniew)

2009-03-01

Tauopathies with parkinsonism: Clinical spectrum, neuropathologic basis, biological markers, and treatment options

Publication

Publication

European Journal of Neurology , Volume 16 - Issue 3 p. 297- 309

Tauopathies with parkinsonism represent a spectrum of disease entities unified by the pathologic accumulation of hyperphosphorylated tau protein fragments within the central nervous system. These pathologic characteristics suggest shared pathogenetic pathways and possible molecular targets for disease-modifying therapeutic interventions. Natural history studies, for instance, in progressive supranuclear palsy, frontotemporal dementia with parkinsonism linked to chromosome 17, corticobasal degeneration, and Niemann-Pick disease type C as well as in amyotrophic lateral sclerosis/Parkinson-dementia complex permit clinical characterization of the disease phenotypes and are crucial to the development and validation of biological markers for differential diagnostics and disease monitoring, for example, by use of neuroimaging or proteomic approaches. The wide pathologic and clinical spectrum of the tauopathies with parkinsonism is reviewed in this article, and perspectives on future advances in the understanding of the pathogenesis are given, together with potential therapeutic strategies.

Additional Metadata
Keywords Corticobasal degeneration, Frontotemporal dementia with parkinsonism linked to chromosome 17, Microtubule-associated protein tau, Multiple system atrophy, Niemann Pick disease, Parkinson disease, Parkinsonism, Progressive supranuclear palsy, Tauopathies, amyotrophic lateral sclerosis, anthraquinone derivative, benzothiazole derivative, biological marker, chromosome 17, clinical feature, corticobasal degeneration, differential diagnosis, drug mechanism, frontotemporal dementia, genetics, history, human, lithium, neuroimaging, neuropathology, nonhuman, parkinsonism, pathogenesis, phenothiazine derivative, phenotype, polyphenol derivative, priority journal, progressive supranuclear palsy, proteomics, rating scale, review, target cell, tau protein, tauopathy, treatment planning
Persistent URL doi.org/10.1111/j.1468-1331.2008.02513.x, hdl.handle.net/1765/18413
Journal European Journal of Neurology
Organisation Erasmus MC: University Medical Center Rotterdam
Citation
Ludolph, A., Kassubek, J., Landwehrmeyer, B. G., Mandelkow, E. M., Burn, D., Caparros-Lefebvre, D., … Wszolek, Z. (2009). Tauopathies with parkinsonism: Clinical spectrum, neuropathologic basis, biological markers, and treatment options. European Journal of Neurology (Vol. 16, pp. 297–309). doi:10.1111/j.1468-1331.2008.02513.x
Full Text ( Final Version )


User Publication Person Organisation Collection
Close